ConductScience.org, home

Trial · NCT05859802

Effects of Physical Therapy and Dalfampridine on Functional Mobility in Non Ambulatory Persons With Multiple Sclerosis

NCT05859802, Phase 2, Phase 3, Completed, D'Youville College

3 sourcestrials-2026-11-12-0.5.0

Download JSON
Cite this record

ConductScience Library. Effects of Physical Therapy and Dalfampridine on Functional Mobility in Non Ambulatory Persons With Multiple Sclerosis. Trials, record NCT05859802. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05859802

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title
Effects of Physical Therapy and Dalfampridine on Functional Mobility in Non Ambulatory Persons With Multiple Sclerosis
NCT number
NCT05859802
Status
Completed
Phases
Phase 2, Phase 3
Enrollment
35 participants, actual
Lead sponsor
D'Youville College
Conditions
Multiple Sclerosis
Interventions
Dalfampridine Pill, Placebo
First posted
2023-05-16
Last updated
2023-05-16

Source ClinicalTrials.gov

Registered outcomes18

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

ListOutcomeTime frameDescription
PrimaryMSQOL -54Baseline
PrimaryMSQOL -546 weeks
PrimaryMSQOL -5412 weeks
PrimaryFive time Sit to StandBaseline
PrimaryFive time Sit to Stand6 weeks
PrimaryFive time Sit to Stand12 weeks
SecondarySymbol Digit Modalities TestBaseline
SecondarySymbol Digit Modalities Test6 weeks
SecondarySymbol Digit Modalities Test12 weeks
SecondaryWheel chair to Mat transfers - Functional Independence MeasureBaseline

Outcomes0

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

None in this release.

Results by group0

Each measurement the trial posted, group by group, in the words and numbers it posted.

None in this release.

Participant flow0

How many started, completed or left each group, period by period.

None in this release.

Adverse events0

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

None in this release.

Adverse event totals0

The totals the trial posted for each group.

None in this release.

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests1

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

TestNamed as
Symbol CodingSecondary outcome

Data dates

The day each source was copied for this release.

ClinicalTrials.gov
2026-11-12
ClinicalTrials.gov
Results, from AACT
2026-03-23
AACT
NIH grant links
2026-11-13
NIH RePORTER

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT05859802

GET https://conductscience.org/api/trials/v1/NCT05859802/registered